Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC.

J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27.

PMID:
29584545
2.

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.

Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirer GG, Satele D, Allred J, Lensing JL, Chen A, Ji J, Zang Y, Erlichman C, Haluska P, Kaufmann SH.

Clin Cancer Res. 2018 Feb 15;24(4):744-752. doi: 10.1158/1078-0432.CCR-17-1590. Epub 2017 Nov 14.

PMID:
29138343
3.

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ.

Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5.

PMID:
28874413
4.

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN.

J Clin Oncol. 2017 Oct 20;35(30):3391-3400. doi: 10.1200/JCO.2017.73.3246. Epub 2017 Aug 30.

PMID:
28854070
5.

A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.

Haddad T, Qin R, Lupu R, Satele D, Eadens M, Goetz MP, Erlichman C, Molina J.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1221-1227. doi: 10.1007/s00280-017-3322-9. Epub 2017 May 5.

PMID:
28477227
6.

A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups.

Yin J, Qin R, Sargent DJ, Erlichman C, Shi Q.

J Biopharm Stat. 2018;28(3):451-462. doi: 10.1080/10543406.2017.1321007. Epub 2017 Jun 7.

PMID:
28448747
7.

Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.

Larsen JT, Shanafelt TD, Leis JF, LaPlant B, Call T, Pettinger A, Hanson C, Erlichman C, Habermann TM, Reeder C, Nikcevich D, Bowen D, Conte M, Boysen J, Secreto C, Lesnick C, Tschumper R, Jelinek D, Kay NE, Ding W.

Am J Hematol. 2017 Aug;92(8):759-763. doi: 10.1002/ajh.24762. Epub 2017 Jun 1.

PMID:
28402581
8.

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.

Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N.

Oncotarget. 2017 May 23;8(21):35326-35338. doi: 10.18632/oncotarget.15108.

9.

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.

Ma CX, Sanchez C, Gao F, Crowder R, Naughton M, Pluard T, Creekmore A, Guo Z, Hoog J, Lockhart AC, Doyle A, Erlichman C, Ellis MJ.

Clin Cancer Res. 2016 Jun 1;22(11):2650-8. doi: 10.1158/1078-0432.CCR-15-2160. Epub 2016 Jan 18.

10.

Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.

Hubbard JM, Kim G, Borad MJ, Johnson E, Qin R, Lensing J, Puttabasavaiah S, Wright J, Erlichman C, Grothey A.

Invest New Drugs. 2016 Feb;34(1):96-103. doi: 10.1007/s10637-015-0308-5. Epub 2015 Nov 18.

11.

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, Beeram M, Molina JR, Rasco DW, Arcos RR, Kelly CS, Wijayawardana SR, Zhang X, Stancato LF, Bell R, Shi P, Kulanthaivel P, Pitou C, Mulle LB, Farrington DL, Chan EM, Goetz MP.

Clin Cancer Res. 2016 Mar 1;22(5):1095-102. doi: 10.1158/1078-0432.CCR-15-1718. Epub 2015 Nov 18. Erratum in: Clin Cancer Res. 2016 May 15;22(10 ):2596.

12.

Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).

Yoon HH, Foster NR, Meyers JP, Steen PD, Visscher DW, Pillai R, Prow DM, Reynolds CM, Marchello BT, Mowat RB, Mattar BI, Erlichman C, Goetz MP.

Ann Oncol. 2016 Feb;27(2):339-44. doi: 10.1093/annonc/mdv543. Epub 2015 Nov 16.

13.

Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).

Ma BB, Goh BC, Lim WT, Hui EP, Tan EH, Lopes Gde L, Lo KW, Li L, Loong H, Foster NR, Erlichman C, King AD, Kam MK, Leung SF, Chan KC, Chan AT.

Invest New Drugs. 2015 Aug;33(4):985-91. doi: 10.1007/s10637-015-0264-0. Epub 2015 Jun 19.

PMID:
26084990
14.

Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.

Pedersen KS, Kim GP, Foster NR, Wang-Gillam A, Erlichman C, McWilliams RR.

Invest New Drugs. 2015 Aug;33(4):963-8. doi: 10.1007/s10637-015-0246-2. Epub 2015 May 8.

15.

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.

Merchan JR, Qin R, Pitot H, Picus J, Liu G, Fitch T, Maples WJ, Flynn PJ, Fruth BF, Erlichman C.

Cancer Chemother Pharmacol. 2015 Mar;75(3):485-93. doi: 10.1007/s00280-014-2668-5. Epub 2015 Jan 3.

16.

Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.

Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman C.

J Clin Oncol. 2015 May 10;33(14):1551-6. doi: 10.1200/JCO.2014.56.2082. Epub 2014 Dec 8.

17.

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK; Mayo Phase 2 Consortium.

Blood. 2015 Jan 15;125(3):443-8. doi: 10.1182/blood-2014-05-573741. Epub 2014 Nov 13.

18.

A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.

Mattison R, Jumonville A, Flynn PJ, Moreno-Aspitia A, Erlichman C, LaPlant B, Juckett MB.

Leuk Lymphoma. 2015 Jul;56(7):2061-6. doi: 10.3109/10428194.2014.977886. Epub 2014 Nov 19.

19.

A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma.

Knox JJ, Qin R, Strosberg JR, Tan B, Kaubisch A, El-Khoueiry AB, Bekaii-Saab TS, Rousey SR, Chen HX, Erlichman C.

Invest New Drugs. 2015 Feb;33(1):241-6. doi: 10.1007/s10637-014-0169-3. Epub 2014 Oct 16.

PMID:
25318437
20.

Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.

Costello BA, Borad MJ, Qi Y, Kim GP, Northfelt DW, Erlichman C, Alberts SR.

Invest New Drugs. 2014 Aug;32(4):710-6. doi: 10.1007/s10637-014-0096-3. Epub 2014 Apr 18.

PMID:
24740268
21.

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C; Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium.

J Clin Endocrinol Metab. 2014 May;99(5):1687-93. doi: 10.1210/jc.2013-3713. Epub 2014 Feb 25.

22.

Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.

Gálvez-Peralta M, Flatten KS, Loegering DA, Peterson KL, Schneider PA, Erlichman C, Kaufmann SH.

Mol Pharmacol. 2014 May;85(5):723-34. doi: 10.1124/mol.113.088674. Epub 2014 Feb 25.

23.

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.

Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM.

Invest New Drugs. 2013 Dec;31(6):1559-67. doi: 10.1007/s10637-013-0034-9. Epub 2013 Oct 10.

24.

Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.

Ding W, Shanafelt TD, Lesnick CE, Erlichman C, Leis JF, Secreto C, Sassoon TR, Call TG, Bowen DA, Conte M, Kumar S, Kay NE.

Br J Haematol. 2014 Jan;164(1):146-50. doi: 10.1111/bjh.12564. Epub 2013 Sep 20. No abstract available.

25.

Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer.

Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, Molina JR.

Anticancer Drugs. 2013 Nov;24(10):1079-83. doi: 10.1097/CAD.0000000000000009.

26.

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.

Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U.

Clin Genitourin Cancer. 2013 Dec;11(4):477-83. doi: 10.1016/j.clgc.2013.05.005. Epub 2013 Jul 26.

27.

Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.

Kumar SK, Jett J, Marks R, Richardson R, Quevedo F, Moynihan T, Croghan G, Markovic SN, Bible KC, Qin R, Tan A, Molina J, Kaufmann SH, Erlichman C, Adjei AA.

Invest New Drugs. 2013 Oct;31(5):1201-6. doi: 10.1007/s10637-013-0004-2. Epub 2013 Jul 26.

28.

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.

Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF.

Breast Cancer Res Treat. 2013 May;139(1):145-53. doi: 10.1007/s10549-013-2528-8. Epub 2013 Apr 19.

29.

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.

Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, Storgard C, Von Hoff D.

Cancer Chemother Pharmacol. 2013 May;71(5):1345-55. doi: 10.1007/s00280-013-2134-9. Epub 2013 Apr 6.

PMID:
23564374
30.

Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.

Schenk E, Hendrickson AE, Northfelt D, Toft DO, Ames MM, Menefee M, Satele D, Qin R, Erlichman C.

Invest New Drugs. 2013 Oct;31(5):1251-6. doi: 10.1007/s10637-013-9946-7. Epub 2013 Mar 31.

31.

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.

Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster NR, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith WA.

Cancer Med. 2012 Oct;1(2):207-17. doi: 10.1002/cam4.27. Epub 2012 Aug 16.

32.

The clinical case for proton beam therapy.

Foote RL, Stafford SL, Petersen IA, Pulido JS, Clarke MJ, Schild SE, Garces YI, Olivier KR, Miller RC, Haddock MG, Yan E, Laack NN, Arndt CA, Buskirk SJ, Miller VL, Brent CR, Kruse JJ, Ezzell GA, Herman MG, Gunderson LL, Erlichman C, Diasio RB.

Radiat Oncol. 2012 Oct 22;7:174. doi: 10.1186/1748-717X-7-174. Review.

33.

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C.

J Oncol Pract. 2012 May;8(3 Suppl):e1s-5s. doi: 10.1200/JOP.2011.000496.

34.

Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.

Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC.

J Clin Oncol. 2012 Sep 20;30(27):3361-7. doi: 10.1200/JCO.2011.41.2395. Epub 2012 Aug 20.

35.

Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.

Holtan SG, Steen PD, Foster NR, Erlichman C, Medeiros F, Ames MM, Safgren SL, Graham DL, Behrens RJ, Goetz MP.

PLoS One. 2012;7(7):e39285. doi: 10.1371/journal.pone.0039285. Epub 2012 Jul 17.

36.

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.

Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, Karlin NJ, Traynor AM, Kumar P, Goh BC, Lim WT, Bossou AR, Isham CR, Webster KP, Kukla AK, Bieber C, Burton JK, Harris P, Erlichman C; Mayo Phase 2 Consortium; Mayo Clinic Endocrine Malignances Disease Oriented Group.

J Clin Endocrinol Metab. 2012 Sep;97(9):3179-84. Epub 2012 Jul 6.

37.

Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.

Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, Roos M, Laumann K, Ghosh AK, Lesnick C, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE.

Cancer. 2013 Jan 15;119(2):363-70. doi: 10.1002/cncr.27719. Epub 2012 Jul 3.

38.

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C.

Am J Manag Care. 2012 May 1;18(5):e162-7.

39.

A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

Bible KC, Peethambaram PP, Oberg AL, Maples W, Groteluschen DL, Boente M, Burton JK, Gomez Dahl LC, Tibodeau JD, Isham CR, Maguire JL, Shridhar V, Kukla AK, Voll KJ, Mauer MJ, Colevas AD, Wright J, Doyle LA, Erlichman C; Mayo Phase 2 Consortium (P2C); North Central Cancer Treatment Group (NCCTG).

Gynecol Oncol. 2012 Oct;127(1):55-62. Epub 2012 Jun 1.

40.

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.

Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P.

Gynecol Oncol. 2012 Feb;124(2):210-5. doi: 10.1016/j.ygyno.2011.10.002. Epub 2011 Nov 1.

41.

Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma.

Ansell SM, Tang H, Kurtin PJ, Koenig PA, Nowakowski GS, Nikcevich DA, Nelson GD, Yang Z, Grote DM, Ziesmer SC, Silberstein PT, Erlichman C, Witzig TE.

Leukemia. 2012 May;26(5):1046-52. doi: 10.1038/leu.2011.297. Epub 2011 Oct 21.

42.

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C.

Cancer. 2012 May 1;118(9):2424-30. doi: 10.1002/cncr.26556. Epub 2011 Sep 27.

43.

A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer.

Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, Murphy SC, Erlichman C, Rudin CM, Govindan R; Mayo Phase 2 Consortium; California Consortium.

J Thorac Oncol. 2011 Oct;6(10):1757-60. doi: 10.1097/JTO.0b013e31822e2941.

44.

Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.

Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P.

Invest New Drugs. 2012 Oct;30(5):1934-41. doi: 10.1007/s10637-011-9742-1. Epub 2011 Sep 1.

45.

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.

Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM.

Haematologica. 2011 Nov;96(11):1619-26. doi: 10.3324/haematol.2011.049551. Epub 2011 Jul 26.

46.

Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.

Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG, Kaufmann SH, Karnitz LM.

Cancer Res. 2011 Jul 15;71(14):4944-54. doi: 10.1158/0008-5472.CAN-11-0814. Epub 2011 May 25.

47.

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).

Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J, LaPlant B, Laumann K, Erlichman C, DiPersio J.

Ann Hematol. 2012 Jan;91(1):33-8. doi: 10.1007/s00277-011-1240-1. Epub 2011 May 3.

48.

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, Ziesmer SC, Feldman AL, Rao R, Gupta M, Erlichman C, Witzig TE.

Lancet Oncol. 2011 Apr;12(4):361-8. doi: 10.1016/S1470-2045(11)70062-6.

49.

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).

Okuno S, Bailey H, Mahoney MR, Adkins D, Maples W, Fitch T, Ettinger D, Erlichman C, Sarkaria JN.

Cancer. 2011 Aug 1;117(15):3468-75. doi: 10.1002/cncr.25928. Epub 2011 Feb 1.

50.

Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.

Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten Eyck C, Nakanishi T, Tibodeau JD, Ross DD, Gottardis MM, Erlichman C, Kaufmann SH, Haluska P.

Mol Cancer Ther. 2011 Jan;10(1):117-25. doi: 10.1158/1535-7163.MCT-10-0438.

Supplemental Content

Loading ...
Support Center